• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 NICE 单一技术评估中的检索:实践和清单。

Assessing searches in NICE single technology appraisals: practice and checklist.

机构信息

School of Health and Related Research, University of Sheffield, United Kingdom.

出版信息

Int J Technol Assess Health Care. 2013 Jul;29(3):315-22. doi: 10.1017/S0266462313000330. Epub 2013 Jun 17.

DOI:10.1017/S0266462313000330
PMID:23769157
Abstract

OBJECTIVES

No guidelines exist in the approach that Evidence Review Groups (ERGs) should take to appraise search methodologies in the manufacturer's submission (MS) in Single Technology Appraisals (STA). As a result, ERGs are left to appraise searches using their own approach. This study investigates the limitations of manufacturers' search methodologies as critiqued by ergs in published sta reports and to provide a recommended checklist.

METHODS

Limitations from search critiques in 83 ERG reports published in the NIHR Web site between 2006 and May 2011 were extracted. The limitations were grouped into themes. Comparisons were made between limitations reported in the clinical effectiveness versus cost-effectiveness searches.

RESULTS

Twelve themes were identified, six relating to the search strategy, source, limits, filters, translation, reporting, and missing studies. The search strategy theme contained the most limitations. Missing studies were frequently found by the ERG group in the clinical effectiveness searches. The omission of searches by manufacturers for unpublished and ongoing trials was frequently reported by the ERG. By contrast, failure of the manufacturer to report strategies was the most common limitation in the cost-effectiveness searches. Themes with the most frequent limitations in both types of searches are search strategy, reporting and source.

CONCLUSIONS

It is recommended that a checklist that has reporting, source and search strategy elements be used in the appraisal of manufacturer's searches during the STA process.

摘要

目的

在单技术评估(STA)中,证据审查小组(ERG)在评估制造商提交的(MS)中搜索方法时,没有指南可循。因此,ERG 只能自行评估搜索。本研究调查了在已发表的 STA 报告中,ERG 批评的制造商搜索方法的局限性,并提供了一份推荐的检查表。

方法

从 2006 年至 2011 年 5 月期间在 NIHR 网站上发表的 83 份 ERG 报告中提取了搜索批评的局限性。将这些局限性分为主题。比较了临床有效性和成本效益搜索中报告的局限性。

结果

确定了 12 个主题,其中 6 个与搜索策略、来源、限制、过滤器、翻译、报告和缺失研究有关。搜索策略主题包含最多的局限性。在临床有效性搜索中,ERG 经常发现缺失的研究。制造商未对未发表和正在进行的试验进行搜索的情况经常被 ERG 报告。相比之下,制造商未报告策略是成本效益搜索中最常见的局限性。在这两种类型的搜索中,最常见的局限性的主题是搜索策略、报告和来源。

结论

建议在 STA 过程中评估制造商搜索时,使用包含报告、来源和搜索策略要素的检查表。

相似文献

1
Assessing searches in NICE single technology appraisals: practice and checklist.评估 NICE 单一技术评估中的检索:实践和清单。
Int J Technol Assess Health Care. 2013 Jul;29(3):315-22. doi: 10.1017/S0266462313000330. Epub 2013 Jun 17.
2
Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.证据审查组对 NICE STA 流程中制造商提交材料进行关键评估的方法:一项映射研究和主题分析。
Health Technol Assess. 2011 May;15(22):1-82, iii-iv. doi: 10.3310/hta15220.
3
The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.在英国国家卫生与临床优化研究所(NICE)单一技术评估过程中使用探索性分析:评估与定性分析。
Health Technol Assess. 2016 Apr;20(26):1-48. doi: 10.3310/hta20260.
4
A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.对制造商向 NICE 单一技术评估(STA)流程提交内容的优缺点进行主题分析。
Health Policy. 2011 Oct;102(2-3):136-44. doi: 10.1016/j.healthpol.2011.06.002. Epub 2011 Jul 16.
5
Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.曲妥珠单抗用于治疗HER2阳性女性原发性乳腺癌:单项技术评估
Health Technol Assess. 2009 Jun;13 Suppl 1:1-6. doi: 10.3310/hta13suppl1/01.
6
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.多西他赛用于早期淋巴结阳性乳腺癌的辅助治疗:单技术评估
Health Technol Assess. 2009 Jun;13 Suppl 1:7-13. doi: 10.3310/hta13suppl1/02.
7
Bortezomib for the treatment of multiple myeloma patients.硼替佐米用于治疗多发性骨髓瘤患者。
Health Technol Assess. 2009 Jun;13 Suppl 1:29-33. doi: 10.3310/hta13suppl1/05.
8
Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病。
Health Technol Assess. 2010 Oct;14(Suppl. 2):19-26. doi: 10.3310/hta14suppl2/03.
9
The use of paclitaxel in the management of early stage breast cancer.紫杉醇在早期乳腺癌治疗中的应用。
Health Technol Assess. 2009 Jun;13 Suppl 1:15-22. doi: 10.3310/hta13suppl1/03.
10
The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.英国国家卫生与临床优化研究所单一技术评估过程中证据审查小组探索性分析的类型及影响
Value Health. 2017 Jun;20(6):785-791. doi: 10.1016/j.jval.2016.08.729. Epub 2016 Oct 21.

引用本文的文献

1
Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial.导管消融与胸腔镜手术消融治疗长期持续性心房颤动(CASA-AF):一项随机对照试验的研究方案
Trials. 2018 Feb 20;19(1):117. doi: 10.1186/s13063-018-2487-9.
2
Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.英国国家卫生与临床优化研究所单一技术评估过程中证据审查小组的探索性分析频率相关问题。
Pharmacoecon Open. 2017 Jun;1(2):99-108. doi: 10.1007/s41669-016-0001-4.
3
Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement.
成本效益决策分析模型关键参数的证据识别:来源描述与推荐的最低检索要求
Pharmacoeconomics. 2016 Jun;34(6):597-608. doi: 10.1007/s40273-015-0372-x.